Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab and somatostatin analog in advanced carcinoid tumors
NCT02795858Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2016
- Primary completion
- Dec 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab in Carcinoid Tumor (CT), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Progression-Free Survival at 23.5 months. Started Jun 2016; status: completed.
02
Drugs
ramucirumab
03
Conditions
Carcinoid Tumor (CT)
Beyond the preview
Go deeper on NCT02795858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02795858.